Insulin-like growth factors 1 and 2, and insuline-like growth factor binding proteins 1 and 3 in bone tumors

Yu.S. Timofeev; N.E. Kushlinskii; I.V. Babkina; O.I. Kostyleva; I.V. Boulytcheva; I.N. Kuznetsov; Yu.N. Soloviev; M.D. Aliev

Insulin-like growth factors 1 and 2, and insuline-like growth factor binding proteins 1 and 3 in bone tumors

Yu.S. Timofeev¹, N.E. Kushlinskii², I.V. Babkina³, O.I. Kostyleva⁴, I.V. Boulytcheva⁵, I.N. Kuznetsov⁶, Yu.N. Soloviev⁷, M.D. Aliev⁸

research article Pages: 33-37

Keywords: insulin-like growth factors (IGF-1 IGF-2)insuline-like growth factor binding proteins (IGFBP-1 IGFBP-3)bone tumors

Abstract

Insulin-like growth factors 1 and 2 (IGF-1 and IGF-2) and insulin-like growth factor binding proteins IGFBP-1, IGFBP-3 were measured by ELISA techniques in blood serum of 113 patients with primary bone tumors. A significant increase of serum IGF-1, 2 and IGFBP-1, 3 levels of bone tumor patients as compared to control group was found; serum IGF-1, 2 levels were significantly increased in malignant bone tumor patients as compared to those with benign neoplasms, and IGFBP-3 levels were increase in benign tumor patients as compared to malignant bone tumor and control groups. Significant differences in markers - levels depending on malignant tumor histological type were revealed.

How to cite

Тимофеев Ю.С., Кушлинский Н.Е., Бабкина И.В., Костылева О.И., Булычева И.В., Кузнецов И.Н., Соловьев Ю.Н., Алиев М.Д. Инсулиноподобные факторы роста и связывающие их белки у больных новообразованиями костей // Технологии живых систем. 2012. № 9. С. 33–37.

References

Clemmons D.R. Value of insulin-likegrowth factor system markers in the assessment of growth hormone status // Endocrinol. Metab. Clin. North. Am. 2007. V. 36. P. 109 - 129.
Frystyk J. Free insulin-like growth factors -Measurements and relationships to growth hormone secretion and glucose homeostasis // Growth Horm. IGF Res. 2004. V. 14. P. 337 - 375.
Vardatsikos G., Sahu A., Srivastava A.K. The Insulin-Like Growth Factor Family: Molecular Mechanisms, Redox Regulation, and Clinical Implications, antioxidants & redoxsignaling // Mary Ann Liebert, Inc. 2009. V. 11. № 5. P.1165.
Dupont J., Pierre A., Froment P., Moreau C. The insulin-like growth factor axis in cell cycle progression // Horm. Metab. Res. 2003. V. 35. P. 740-750.
Zhuang D., Ceacareanu A.C., Lin Y., Ceacareanu B., Dixit M., Chapman K.E., Waters C.M., Rao G.N., Hassid A. Nitric oxide attenuate sinsulin-or IGF-I-stimulated aortics mooth muscle cell motility by decree sing H₂O₂ levels: Essential role of cGMP // Am. J. Physiol. Heart Circ. Physiol. 2004. V. 286. P. H2103 - H2112.
Fukuda R., Hirota K., Fan F., Jung Y.D., Ellis L.M., Semenza G.L. Insulin-like growth factor 1 induces hypoxia-inducible factor1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells // J. Biol. Chem. 2002. V. 277. P. 38205 - 38211.
Conover C.A. Insulin-like growth factor-binding proteins and bone metabolism // Am. J. Physiol.
Endocrinol. Metab. 2008. V. 294. P. E10-14.
Ulaner G.A., Vu T.H., Li T., Hu J.F., Yao X.M., Yang Y. Loss of imprinting of IGF2 and H19 in osteosarcoma is accompanied by reciprocal methylation changes of a CTCF-binding site // Hum. Mol. Genet. 2003. V. 12. P. 535 - 549.
Riggi N., Cironi L., Provero P., Suva M.L., Kaloulis K., Garcia-Echeverria C. Development of Ewing-s sarcoma from primary bone marrow-derived mesenchymal progenitor cells // Cancer Res. 2005. V. 65. P. 11459 - 11468.
Kageyama K., Moriyama T., Hizuka N., Sakihara S., Takayasu S., Tamasawa N., Suda T. Hypoglycemica Associated with Big Insulin-Like Growth Factor II Produced during Developmen of Malignant Gibrous Hisiocytoma // End. J. 2003. V. 50. № 6. P. 753 - 758.
Rikhof B., de Jong S., Suurmeijer A.J., Meijer C., van der Graaf W.T. The insulin-like growth factor system and sarcomas // J. Pathol. 2009. V. 217. P. 469 - 482.
Samani A.A., Yakar S., Le Roith D., Brodt P. The Role of the IGF System in Cancer Growth and Metastasis: Overview and Recent Insights // Endocrine Reviews. 2007. V. 28. № 1. P. 20 - 47.
Tang Y., Zhang D., Fallavollita L., Brodt P. Vascular endothelial growth factor C expression and lymph node metastasis are regulated by the type I insulin-like growth factor receptor // Cancer Res. 2003. V. 63. P. 1166 - 1171.
Firth S., Baxter R. Cellular Actions of the Insulin-Like Growth Factor Binding Proteins // Endocrine Reviews. 2002. V. 23. P. 824 - 854.

[1] Clemmons D.R. Value of insulin-likegrowth factor system markers in the assessment of growth hormone status // Endocrinol. Metab. Clin. North. Am. 2007. V. 36. P. 109 - 129.

[2] Frystyk J. Free insulin-like growth factors -Measurements and relationships to growth hormone secretion and glucose homeostasis // Growth Horm. IGF Res. 2004. V. 14. P. 337 - 375.

[3] Vardatsikos G., Sahu A., Srivastava A.K. The Insulin-Like Growth Factor Family: Molecular Mechanisms, Redox Regulation, and Clinical Implications, antioxidants & redoxsignaling // Mary Ann Liebert, Inc. 2009. V. 11. № 5. P.1165.

[4] Dupont J., Pierre A., Froment P., Moreau C. The insulin-like growth factor axis in cell cycle progression // Horm. Metab. Res. 2003. V. 35. P. 740-750.

[5] Zhuang D., Ceacareanu A.C., Lin Y., Ceacareanu B., Dixit M., Chapman K.E., Waters C.M., Rao G.N., Hassid A. Nitric oxide attenuate sinsulin-or IGF-I-stimulated aortics mooth muscle cell motility by decree sing H₂O₂ levels: Essential role of cGMP // Am. J. Physiol. Heart Circ. Physiol. 2004. V. 286. P. H2103 - H2112.

[6] Fukuda R., Hirota K., Fan F., Jung Y.D., Ellis L.M., Semenza G.L. Insulin-like growth factor 1 induces hypoxia-inducible factor1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells // J. Biol. Chem. 2002. V. 277. P. 38205 - 38211.

[7] Conover C.A. Insulin-like growth factor-binding proteins and bone metabolism // Am. J. Physiol.
Endocrinol. Metab. 2008. V. 294. P. E10-14.

[8] Ulaner G.A., Vu T.H., Li T., Hu J.F., Yao X.M., Yang Y. Loss of imprinting of IGF2 and H19 in osteosarcoma is accompanied by reciprocal methylation changes of a CTCF-binding site // Hum. Mol. Genet. 2003. V. 12. P. 535 - 549.

[9] Riggi N., Cironi L., Provero P., Suva M.L., Kaloulis K., Garcia-Echeverria C. Development of Ewing-s sarcoma from primary bone marrow-derived mesenchymal progenitor cells // Cancer Res. 2005. V. 65. P. 11459 - 11468.

[10] Kageyama K., Moriyama T., Hizuka N., Sakihara S., Takayasu S., Tamasawa N., Suda T. Hypoglycemica Associated with Big Insulin-Like Growth Factor II Produced during Developmen of Malignant Gibrous Hisiocytoma // End. J. 2003. V. 50. № 6. P. 753 - 758.

[11] Rikhof B., de Jong S., Suurmeijer A.J., Meijer C., van der Graaf W.T. The insulin-like growth factor system and sarcomas // J. Pathol. 2009. V. 217. P. 469 - 482.

[12] Samani A.A., Yakar S., Le Roith D., Brodt P. The Role of the IGF System in Cancer Growth and Metastasis: Overview and Recent Insights // Endocrine Reviews. 2007. V. 28. № 1. P. 20 - 47.

[13] Tang Y., Zhang D., Fallavollita L., Brodt P. Vascular endothelial growth factor C expression and lymph node metastasis are regulated by the type I insulin-like growth factor receptor // Cancer Res. 2003. V. 63. P. 1166 - 1171.

[14] Firth S., Baxter R. Cellular Actions of the Insulin-Like Growth Factor Binding Proteins // Endocrine Reviews. 2002. V. 23. P. 824 - 854.